ReviewTranslational lung cancer research2026
Targeted therapy for stage IA non-small cell lung cancer with
Review in Translational lung cancer research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Patients with stage IA epidermal growth factor receptor ( Methods: This scoping review was conducted following PRISMA-ScR. Searches of nine literature databases and six clinical trial registries were completed on June 18, 2025. Literature selection and data extraction were performed using double-blinded and third-party arbitration methods. Findings were categorized into direct evidence, indirect evidence, and ongoing trials, visualized in tabular and graphical formats. Results: We retrieved 3,308 records. After a two-step screening process, 33 published studies and 22 ongoing clinical trials were retained. Among the 33 publications, 12 served as direct evidence sources and 21 as indirect evidence sources, all reporting potential benefits of EGFR-tyrosine kinase inhibitors (EGFR-TKIs). Publications release and clinical trials initiation were concentrated after 2020, with China as the primary country of conduct. Among the studies, first-generation erlotinib and third-generation osimertinib were the most frequently used agents. Common high-risk factors included micropapillary, solid, complex gland components (CGC), spread through air spaces (STAS), minimal residual disease (MRD), and lymphovascular invasion (LVI). Conclusions: Direct evidence for targeted therapy in patients with stage IA
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.